**Summary**
Cambridge Cognition Holdings PLC, a neuroscience technology company, released a trading update for the year ended 31 December 2025, highlighting significant progress in its commercial activities and financial performance. Key points include
1. **Strong Sales Growth**New sales orders increased by 73% to £12.8 million, with a 25% rise in the order book to £16.9 million.
2. **Revenue and EBITDA**Revenues declined by 10% to £9.4 million due to a weak 2024 order book, but adjusted EBITDA loss aligned with market expectations.
3. **Financial Position**Cash improved to £1.1 million, with a net cash position of £0.2 million after reducing borrowings and a successful £1.1 million placing in August 2025.
4. **Strategic Expansion**Launched **CANTAB Pathwayâ„¢**, a new solution for professional healthcare, with a significant pilot program signed with a major European private healthcare group. Progress also noted in consumer health and wellness markets.
5. **Outlook for 2026**Strong pipeline of opportunities, expected growth in sales orders, and continued development in consumer health markets. The company anticipates revenue growth, improved earnings, and cash generation in 2026.
CEO Rob Baker expressed confidence in the company’s strengthened commercial execution, enhanced product offerings, and growth prospects, emphasizing its commitment to neuroscience excellence and technology innovation.